Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

sults, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

  • our ability to borrow additional amounts under the loan agreement, which is subject to the discretion of the Lender;
  • our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan by the September 14, 2009 maturity date;
  • our ability to control our operating expenses;
  • our failure to timely recruit and enroll patients for the FDG-PET clinical trial, as well as any future clinical trial;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays;

  • '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 19, 2014 Research and Markets ... addition of the "Technology Innovations in Smart ... http://photos.prnewswire.com/prnh/20130307/600769 ... Smart Fabrics" offers a detailed assessment on technological ... Key Findings: 1. The Smart ...
(Date:12/19/2014)... 18, 2014 Reports from CDC ... States suffer from one or more chronic health conditions ... Medication can address some of these diseases, but may ... many sufferers face. While implanted nerve stimulation devices today ... whole nerve, which can induce side effects. , ...
(Date:12/19/2014)...  Decision Resources Group finds that the ... moderately through 2023 as the aging population, increasing adoption ... biomaterials all spur procedure volumes. Growth will be particularly ... and India , where ... for a larger proportion of the population. ...
(Date:12/17/2014)... Based on the revenues gained from surgical imaging ... by four major players contributing to approximately 74% ... GE Healthcare (U.K.), Siemens AG (Germany), Philips (Netherlands), ... Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The leading ... its strong product portfolio, which includes its flagship ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Pharma AG, today,announced a substantial expansion of its ... Medical Officer and Head of Global Clinical,Development, Dr. ... Dr,Hans Rensland as Vice President Regulatory Affairs, Dr. ... Dr. Markus Vogt as Vice,President of Quality and ...
... A combination of two drugs can selectively block pain-sensing ... such as touch, according to a new study by ... suggests an improved way to treat pain from childbirth ... new treatments to help the millions of Americans who ...
... Troy J. Campione, Ph.D., Joins Solazyme Executive Team, ... Solazyme, a,bioscience company pioneering biofuels and health/wellness products ... the position of senior,vice president of business development. ... finalization of,partnership agreements and contracts with major companies. ...
Cached Biology Technology:Nitec Pharma Expands Senior Management Team 2Nitec Pharma Expands Senior Management Team 3Nitec Pharma Expands Senior Management Team 4Treatment blocks pain without disrupting other functions 2Treatment blocks pain without disrupting other functions 3Solazyme Announces New Senior Vice President of Business Development 2
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... GBIF Campaign? , Different users of the GBIF network ... of various types. Given the small size and coordination ... central activities to meet all of these needs. However, ... the GBIF network do coincide with the needs of these ...
... wont be making a stop at the Smithsonians National ... with love and romance, mating and dating at the ... encounter. Successful breeding is often much more complicated ... nature to take its course. Animals in captivity need ...
... coursing through the veins of men living in the North ... has been just published. Focusing on the Wirral in ... surnames were in existence as far back as medieval times, ... specifically linked to Scandinavian ancestry. The collaborative study, by ...
Cached Biology News:4 GBIF-endorsed campaigns underway 24 GBIF-endorsed campaigns underway 34 GBIF-endorsed campaigns underway 44 GBIF-endorsed campaigns underway 5Science, not romance, controls mating at Smithsonian's National Zoo 2Science, not romance, controls mating at Smithsonian's National Zoo 3Unravelling the Northwest's Viking past 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... apoptosis in mammalian cells. The CaspSCREEN ... simple and convenient means for detecting activation ... cells. The assay utilizes a substrate ... rhodamine 110 (D2R), a reported substrate for ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: